Celgene Announces Retirement of President & Chief Operating Officer, Jacqualyn Fouse, Ph.D. & Promotion of Scott Smith to Pre...
February 23 2017 - 4:30PM
Business Wire
- Jacqualyn Fouse, Ph.D., to retire from
Celgene effective June 30, 2017 and will not stand for reelection
to the Celgene Board of Directors
- Scott Smith to be promoted to President and
Chief Operating Officer, effective April 1, 2017
- Terrie Curran to be promoted to President,
Global Inflammation & Immunology Franchise, effective April 1,
2017
Celgene Corporation (NASDAQ:CELG) today announced that President
and Chief Operating Officer (COO) Jacqualyn (“Jackie”) Fouse,
Ph.D., has decided to retire from Celgene effective June 30, 2017.
She will continue to serve as President and COO until April 1, and
through June 30, she will serve as a strategic advisor to the
management team. Jackie will not stand for reelection to the
Celgene Board of Directors at the upcoming Annual Meeting in June.
The Company also announced the promotion of Scott Smith to
President and COO, effective April 1, 2017, and the promotion of
Terrie Curran to President, Global Inflammation & Immunology
(I&I) Franchise, effective April 1, 2017.
Jackie joined Celgene in 2010 as Chief Financial Officer. In
2014, she was appointed President of Celgene’s Hematology &
Oncology Franchise and in 2016 she was promoted to President and
COO. Throughout Jackie’s nearly seven years with the Company,
Celgene has produced tremendous growth and outstanding results.
“I would like to thank Jackie for her incredible commitment and
dedication to Celgene and the patients we seek to serve worldwide,”
said Mark Alles, Chief Executive Officer of Celgene. “On behalf of
all Celgene employees, I wish Jackie the best in her
retirement.”
In 2016, Jackie was elected to Celgene’s Board of Directors. In
connection with announcing her decision to retire from Celgene, she
informed the Board that she would not stand for reelection to the
Celgene Board.
“Celgene has greatly benefited from Jackie’s strategic
leadership and wisdom,” said Bob Hugin, Executive Chairman of
Celgene Corporation. “All of us thank Jackie for her countless and
meaningful contributions to Celgene.”
Scott Smith, will be promoted to President and COO, effective
April 1, 2017. Scott joined Celgene in 2008 and successfully built
and launched Celgene’s I&I Franchise. Under Scott’s leadership,
OTEZLA® has achieved tremendous commercial success and Celgene has
built a robust and high-potential I&I pipeline. Scott has
thirty years of experience in the biopharmaceutical industry
spanning commercial, business strategy and general management roles
across multiple countries and therapeutic areas. Before joining
Celgene, Scott served as Global Commercial Head for Biovail.
“Scott is a tremendous leader with extensive industry experience
and his teams have consistently delivered outstanding results,”
said Mark Alles. “Our entire organization will benefit from Scott’s
business expertise, strategic leadership, and focus on operational
excellence.”
Terrie Curran will be promoted to President, Global I&I
Franchise, effective April 1, 2017. She joined Celgene in 2013 as
the U.S. Commercial Head of the I&I Franchise and established
the framework and built the capabilities for the successful U.S.
launch of OTEZLA®. In early 2016, Terrie was promoted to Head of
Worldwide Commercial Markets for the I&I Franchise and is
leading the worldwide launch of OTEZLA®. Prior to joining Celgene,
Terrie was a Senior Vice President at Merck, where she led the
Global Women’s Health franchise from 2009-2013.
“Terrie has been instrumental in establishing Celgene as a
leader in the inflammation and immunology marketplace,” said Mark
Alles. “Terrie’s knowledge of our business and strategic
capabilities will greatly benefit Celgene as we continue to build a
preeminent global Inflammation & Immunology Franchise.”
About Celgene
Celgene Corporation, headquartered in Summit, New Jersey, is an
integrated global biopharmaceutical company engaged primarily in
the discovery, development and commercialization of innovative
therapies for the treatment of cancer and inflammatory diseases
through gene and protein regulation. For more information, please
visit www.celgene.com. Follow Celgene on Social Media: @Celgene,
Pinterest, LinkedIn, Facebook and YouTube.
Forward-Looking Statements
This press release contains forward-looking statements, which
are generally statements that are not historical facts.
Forward-looking statements can be identified by the words
"expects," "anticipates," "believes," "intends," "estimates,"
"plans," "will," “outlook” and similar expressions. Forward-looking
statements are based on management’s current plans, estimates,
assumptions and projections, and speak only as of the date they are
made. We undertake no obligation to update any forward-looking
statement in light of new information or future events, except as
otherwise required by law. Forward-looking statements involve
inherent risks and uncertainties, most of which are difficult to
predict and are generally beyond our control. Actual results or
outcomes may differ materially from those implied by the
forward-looking statements as a result of the impact of a number of
factors, many of which are discussed in more detail in our Annual
Report on Form 10-K and our other reports filed with the Securities
and Exchange Commission.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170223006688/en/
Celgene CorporationInvestors:Patrick E. Flanigan III,
908-673-9969Corporate Vice PresidentInvestor RelationsorMedia:Brian
P. Gill, 908-673-9530Vice PresidentCorporate Communications
Celgene (NASDAQ:CELG)
Historical Stock Chart
From Mar 2024 to Apr 2024
Celgene (NASDAQ:CELG)
Historical Stock Chart
From Apr 2023 to Apr 2024